Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations-Reference-Cited by-同舟云学术

Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations

Published:2016-02-08 Issue:2 Volume:18 Page:505-518
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Aoki Yasunori,Nordgren Rikard,Hooker Andrew C.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-016-9866-5.pdf

Reference17 articles.

1. Benzi M. Preconditioning techniques for large linear systems: a survey. J Comput Phys. 2002;182(2):418–77.

2. Morikuni K, Hayami K. Convergence of inner-iteration GMRES methods for rank-deficient least squares problems. SIAM J Matrix Anal Applic. 2015;36(1):225–50.

3. Keizer RJ, Karlsson MO, Hooker AC. Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT: Pharmacomet Syst Pharmacol. 2013;2:e50.

4. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. Proceedings of the fifth Berkeley symposium on mathematical statistics and probability. 1967;1(1).

5. Kauermann G, Carroll RJ. A note on the efficiency of sandwich covariance matrix estimation. J Am Stat Assoc. 2001;96(456):1387–96.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bayesian estimation in NONMEM;CPT: Pharmacometrics & Systems Pharmacology;2023-12-08

2. nlmixr2extra: Nonlinear Mixed Effects Models in Population PK/PD, Extra Support Functions;CRAN: Contributed Packages;2022-05-17

3. Metaheuristics for pharmacometrics;CPT: Pharmacometrics & Systems Pharmacology;2021-10-22

4. Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates;Clinical Pharmacokinetics;2021-10-07

5. cLRT‐Mod : An efficient methodology for pharmacometric model‐based analysis of longitudinal phase II dose finding studies under model uncertainty;Statistics in Medicine;2021-03-02